Evidence map›Paper›PMID 40381904›Full record

ArticleExperimental neurology2025

Anti-Nogo-A antibody treatment six months post-stroke results in neuroplasticity and improved functional outcome.

Shih-Yen Tsai, Son T Ton, Timothy E O'Brien, Douglas G Wallace, Russ P Nockels, Gwendolyn L Kartje

Abstract read
In one paragraph

Article in Experimental neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shih-Yen TsaiResearch Service, Edward Hines Jr. Veterans Affairs Hospital, Hines, IL, USA. Electronic address: shih-yen.tsai@va.gov.
Son T TonResearch Service, Edward Hines Jr. Veterans Affairs Hospital, Hines, IL, USA.
Timothy E O'BrienDepartment of Mathematics and Statistics, Loyola University Chicago, Chicago, IL, USA.
Douglas G WallaceDepartment of Psychology, Northern Illinois University, DeKalb, IL, USA.
Russ P NockelsDepartment of Neurosciences, Intent Medical Group, Endeavor Neurosciences Institute, Arlington Heights, IL, USA.
Gwendolyn L KartjeResearch Service, Edward Hines Jr. Veterans Affairs Hospital, Hines, IL, USA; Department of Molecular Pharmacology and Neuroscience, Loyola University Chicago Health Sciences Division, Maywood, IL, USA.

Funding

Novel approaches to stimulating neurotrophin signaling for stroke recoveryR01NS115759 · NINDS · CHICAGO ASSN FOR RESEARCH & EDUC IN SCI · PI KARTJE, GWENDOLYN LOUISE · 2020 to 2023
$1.5M
NINDS NIH HHS R01 NS115759
6 · The paper itself

Abstract

We have reported that anti-Nogo-A antibody therapy is effective in enhancing neuroplasticity and improving functional recovery when given up to two months post-stroke. Here we assessed whether this therapy would be effective at a much later time point post-stroke. Rats underwent middle cerebral artery occlusion to permanently impair their preferred forelimb and six months later were given either anti-Nogo-A antibody, control antibody or no antibody. Rats receiving anti-Nogo-A antibody showed significant behavioral improvement that correlated with cortico-rubral plasticity, indicating that anti-Nogo-A antibody is effective even long after the injury has occurred, opening the treatment window for many stroke survivors.

Indexed as

AntibodiesNeuronal PlasticityNogo ProteinsRecovery of FunctionStrokeAnimalsInfarction, Middle Cerebral ArteryMaleRatsRats, Sprague-DawleyTime FactorsTreatment OutcomeAntibodiesNogo ProteinsNogo-APlasticityRecoveryStroke

Identifiers

PMID40381904
PMCPMC12435590

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.